Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C.
about
Ribavirin Quantification in Combination Treatment of Chronic Hepatitis CReduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug ResistanceRibavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort StudyUse of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitisRole of ITPA gene polymorphism in ribavirin-induced anemia and thrombocytopenia in Egyptian patients with chronic hepatitis C.Treatment of hepatitis C virus infection: updated Swedish Consensus recommendations.Developments in the treatment of chronic hepatitis C.The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections.Liquid chromatography-tandem mass spectrometry--application in the clinical laboratory.Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients.Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infectionPharmacokinetics of ribavirin in patients with hepatitis C virus.Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infectionPredicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.The management of side-effects during therapy for hepatitis C.Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirinPopulation pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infectionRandomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirinInfluence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection.Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus.Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple TherapySeveral factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C.Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture modelsIssues in designing and interpreting clinical trials of treatments for chronic hepatitis C.Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy.Retreatment of chronic hepatitis C in previous non-responders and relapsers.Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1.Ribavirin in the treatment of chronic hepatitis C.The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C--a critical review.Role of ribavirin in HCV treatment response: now and in the future.Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations.Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations.Selection of hepatitis C virus resistant to ribavirin.Patient Characteristics Associated with HCV Treatment Adherence, Treatment Completion, and Sustained Virologic Response in HIV Coinfected Patients.Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.Liquid chromatography assay for routine monitoring of cellular ribavirin levels in blood.ITPA gene variation and ribavirin-induced anemia in patients with genotype 2 chronic hepatitis C treated with sofosbuvir plus ribavirin.Feasibility of ribavirin therapeutic drug monitoring in hepatitis C.Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation.
P2860
Q27473304-6E0F8947-D150-49A9-BBCC-1023BE26CF6DQ27488307-59FA12D0-42FE-41E1-83FE-22D667500D90Q28546829-942C9BE3-CCB5-4B12-B74B-D4F2AAB8112AQ33394544-261D8520-FED0-436E-BF93-210325EFF53DQ33430028-7CEE522B-EA99-4682-95F1-F113C3A6973FQ34087387-BBE02576-E871-449F-A99A-2FF2660F855EQ34581499-73BBF431-E4BA-442D-8224-11E38D73B0F0Q34996746-71943F9D-2166-40BE-B554-219A7A1A9936Q35073553-F254E17E-2303-4298-8AC6-78F102AF3DD0Q35095109-7263C3CE-6BE3-4E75-9AE6-498BF65AD940Q35125818-6955EE58-7107-44FE-AAAC-D2BCB09F3B62Q35169059-80D2F9F1-1DBB-4348-99CD-992C797715C6Q35648745-C3B6A070-9058-4977-83B9-16DD47FC13E6Q35825285-7A5FF71A-CCB7-405F-BEF2-F9FDAA742455Q35827938-6FC9302E-9D11-4D83-B5CE-1C48A68421FCQ35936934-418A935C-FA0D-449D-9A3A-F252EDC27F4CQ35941302-4AAD5B09-C78C-4F7E-AEFA-6DEAD6759BDBQ36065593-22F1C058-1355-4B59-878C-D05449C378C0Q36066514-40DEE88C-A389-4D3D-8633-7462E3109271Q36070215-0112A9D8-6CC4-48D3-8263-8A764590E4DDQ36146443-1F8DFB0C-8724-488B-A8C0-43CEA23C7BE4Q36180241-D581EBF6-CCA2-48AC-ABD5-4D8E66CCC637Q36378784-B3877E5E-27BF-4475-9467-1078DF6EBE3DQ36399860-29BA589C-4AE1-432A-B070-5348B76FE7E3Q36455986-4FC618D0-099B-46D7-8916-7E9E993C37FCQ36775650-1A302267-6862-436B-B297-5A628CDF4CA5Q36968144-F417E2E5-B62F-4B0A-BD85-BA845EA193BDQ37032096-BF96A546-D1E1-4CEC-8CD8-3E7243C64714Q37195248-1A2912EC-2CA4-456A-AF6D-56CDB0305248Q37634196-7087DF69-E465-4980-830C-6A23C35AFB84Q37693948-CF7A595B-F07A-45F3-974B-FAD0B6C9EAC0Q38002889-CE2596A4-C911-457E-8450-AA07801D5D09Q38203823-8429B527-377B-4D11-A0B4-B786AC05E713Q38269623-8BEE09BA-CBAD-496C-82D4-979F56144581Q38894961-252E6D07-FDCE-4261-B073-488CAB243BFFQ39357557-CAA22B60-4985-43D4-A2B2-1AB90685D854Q40164303-DFBEED4D-CCF8-4005-9665-86AB04B632BDQ40362177-CB4ACEB9-8E34-4DEB-AFD5-3970254666E9Q41144825-CA81D7FC-A937-447E-B164-2F2EE0B5B4EFQ41504212-88CE9FF9-4030-4651-8843-58A73B1A301A
P2860
Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Population pharmacokinetic and ...... ents with chronic hepatitis C.
@en
Population pharmacokinetic and ...... ents with chronic hepatitis C.
@nl
type
label
Population pharmacokinetic and ...... ents with chronic hepatitis C.
@en
Population pharmacokinetic and ...... ents with chronic hepatitis C.
@nl
prefLabel
Population pharmacokinetic and ...... ents with chronic hepatitis C.
@en
Population pharmacokinetic and ...... ents with chronic hepatitis C.
@nl
P2093
P1476
Population pharmacokinetic and ...... ents with chronic hepatitis C.
@en
P2093
P304
P356
10.1097/00007691-200010000-00010
P50
P577
2000-10-01T00:00:00Z